The DOI matches its Crossref record.
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
Open accessAbstract
Mutations in the gene encoding the p110α subunit of PI3K (PIK3CA) that result in enhanced PI3K activity are frequently observed in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis, we generated mice in which a PIK3CA mutation commonly detected in human cancers (the H1047R mutation) could be conditionally knocked into the endogenous Pik3ca locus. Activation of this mutation in the mouse ovary revealed that alone, Pik3caH1047R induced premalignant hyperplasia of the ovarian surface epithelium but no tumors. Concomitantly, we analyzed several human ovarian cancers and found PIK3CA mutations coexistent with KRAS and/or PTEN mutations, raising the possibility that a secondary defect in a co-regulator of PI3K activity may be required for mutant PIK3CA to promote transformation. Consistent with this notion, we found that Pik3caH1047R mutation plus Pten deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and granulosa cell tumors. Both mutational events were required for early, robust Akt activation. Pharmacological inhibition of PI3K/mTOR in these mice delayed tumor growth and prolonged survival. These results demonstrate that the Pik3caH1047R mutation with loss of Pten is enough to promote ovarian cell transformation and that we have developed a model system for studying possible therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
The relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., Baxendale, H., Coulter, T., Curtis, J., Wu, C., et al. (2013) · Science · doi:10.1126/science.1243292 · Cited by 636
Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596
Luks, V. L., Kamitaki, N., Vivero, M. P., Uller, W., Rab, R., Bovée, J. V. M. G., Rialon, K. L., Guevara, C. J., Alomari, A. I., Greene, A. K., et al. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.12.069 · Cited by 583
Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome
Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer, S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P. W., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.05.006 · Cited by 532
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
“Conditional expression of p110a-H1047R from the targeted knock-in allele or transgenic expression of Myr-p110a induced premalignant hyperplasia of the ovarian surface epithelium, but no tumors (Liang et al. 2009; Kinross et al. 2012).”
BackgroundMosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Lindhurst, M. J., Parker, V. E. R., Payne, F., Sapp, J. C., Rudge, S., Harris, J., Witkowski, A. M., Zhang, Q., Groeneveld, M. P., Scott, C. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2332 · Cited by 325
Chandler, R. L., Damrauer, J. S., Raab, J. R., Schisler, J. C., Wilkerson, M. D., Didion, J. P., Starmer, J., Serber, D., Yee, D., Xiong, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7118 · Cited by 323
A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma
Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R.-P., Rabinovich, B. A., Hann, B., Dankort, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0347 · Cited by 320
Self-citationRole of Phospholipids in Endocytosis, Phagocytosis, and Macropinocytosis
Bohdanowicz, M., & Grinstein, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00002.2012 · Cited by 311
Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrum
Keppler‐Noreuil, K. M., Sapp, J. C., Lindhurst, M. J., Parker, V. E. R., Blumhorst, C., Darling, T., Tosi, L. L., Huson, S. M., Whitehouse, R. W., Jakkula, E., et al. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36552 · Cited by 305
Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300
“Mice with the most common p110α mutation (H1047R) expressed in ovaries develop hyperplasias, but not tumors, whereas coupled with the loss of the lipid phosphatase PTEN results in rapid ovarian tumor development (9).”
BackgroundDouble PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer
Bollu, L. R., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0934 · Cited by 168
Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis
Mukherjee, R., Vanaja, K. G., Boyer, J. A., Gadal, S., Solomon, H., Chandarlapaty, S., Levchenko, A., & Rosen, N. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.033 · Cited by 135
“Our results are consistent with those obtained by others in genetically engineered mouse models in which PIK3CA mutants have been shown to cooperate with PTEN loss to accelerate disease progression (Kinross et al., 2012; Pearson et al., 2018; Schade et al., 2009) and in breast cancer patients in whom PTEN loss has bee…”
ResultTracing oncogene-driven remodelling of the intestinal stem cell niche
Yum, M. K., Han, S., Fink, J., Wu, S.-H. S., Dabrowska, C., Trendafilova, T., Mustata, R., Chatzeli, L., Azzarelli, R., Pshenichnaya, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03605-0 · Cited by 114
PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
“To test the consequences of elevated PI3’-lipid signaling on KRAS-initiated lung tumorigenesis, we generated compound KRas, Pik3ca (Pik3ca) heterozygous mice (KPi mice) as well as appropriate controls heterozygous for each allele (7,18).”
BackgroundMethodInfluential
Metadata
- Authors
- Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., Sheppard, K. E., Ryland, G. L., Campbell, I. G., Gorringe, K. L., Christensen, J. G., Cullinane, C., Hicks, R. J., Pearson, R. B., Johnstone, R. W., McArthur, G. A., & Phillips, W. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 553-557
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1967187359
- Cited by
- 214
- References
- 0
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.